Business
Radiopharm Theranostics tanks on ASX debut – The Australian Financial Review
The paper value of chairman Paul Hopper’s 35.5 per cent stake fell from $54 million to $36 million in just a few hours.
The early stage company does not have revenue from licence arrangements or product sales. It is developing a platform of radiopharmaceutical products for diagnostic and therapeutic cancer treatment.
Shanghai-based NanoMab Technologies is the second-largest…
Continue Reading
-
Noosa News18 hours agoQueensland GP accused of rape, sexual assault and torture pleads for bail despite ‘disturbing’ allegations
-
General19 hours agoDavid Littleproud’s own goal • Inside Story
-
Noosa News19 hours agoDesperate search for missing Queensland teen Phoebe Bishop pushes into remote bushland
-
General11 hours agoCoalition to chart path forward as family feud cooled